SCHEMBL5308353

SCHEMBL5308353

CC(C)(Nc1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
P2RX7 Q99572 1/20 0.41
MAPKAPK2 P49137 2/20 0.41
VNN1 O95497 2/20 0.40
CNR1 P21554 1/20 0.40
NOX1 Q9Y5S8 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CDC7 O00311 1/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
PDPK1 O15530 1/20 0.39
DAPK3 O43293 1/20 0.39
DYRK3 O43781 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PAK4 O96013 1/20 0.39
PRKCG P05129 1/20 0.39
ROS1 P08922 1/20 0.39
PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL450601 0.85 MAPKAPK2 (0.46) P2RX7MAPKAPK2VNN1CDK2ALDH1A1
Hydrochloric Acid SCHEMBL8507149 0.83 MAPKAPK2 (0.45) P2RX7MAPKAPK2VNN1CDK2ALDH1A1
SCHEMBL18723698 0.82 AKT1 (0.42) P2RX7MAPKAPK2VNN1CDK2AKT1
SCHEMBL18723699 0.82 NR3C2 (0.42) MAPKAPK2VNN1MEN1KMT2ACDK2
SCHEMBL12974365 0.82 HPGD (0.50) MAPKAPK2VNN1MEN1KMT2ACDK2
SCHEMBL28897187 0.82 ALDH1A1 (0.54) POLBMAPKAPK2VNN1MEN1KMT2A
SCHEMBL18435383 0.81 PDE4A (0.42) P2RX7MAPKAPK2VNN1ALDH1A1GAA
SCHEMBL2034204 0.81 MAPKAPK2 (0.42) P2RX7MAPKAPK2VNN1CDK2ALDH1A1
SCHEMBL9276779 0.80 MAPT (0.48) MAPKAPK2VNN1MEN1KMT2ACDK2
SCHEMBL15903895 0.80 ESR1 (0.55) MAPKAPK2VNN1KMT2AALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007017652-A2 ARYLAKYLAMINES FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2007-02-15 WO claimed
EP-2948135-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS Case Western Reserve University (US) 2015-12-02 EP disclosed
WO-2014117089-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS CASE WESTERN RESERVE UNIVERSITY (US) 2014-07-31 WO disclosed
WO-2007017652-A2 ARYLAKYLAMINES FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2007-02-15 WO disclosed